Please login to the form below

Not currently logged in
Email:
Password:

Actelion announces results

Half-year financial results for Swiss biopharmaceutical company, Actelion, show net revenue is up 27 per cent compared to the same period last year

Half-year financial results for Swiss biopharmaceutical company, Actelion, show net revenue is up 27 per cent compared to the same period last year at CHF 855.2m. The company reported an operating profit of CHF 242.9m compared to CHF 137.2m in H1 2008.

During the six months of 2009, sales of the company's pulmonary arterial hypertension (PAH) drug, Tracleer, reached CHF 739.3m – representing an increase of 23 per cent (in local currencies) compared to the first six months of 2008. The European Commission approved the paediatric dispersible formulation of Tracleer for treatment of PAH in children earlier this month. Sales of Ventavis (also for PAH) increased by 50 per cent in local currencies from CHF 37.9m, in H1 2008 to CHF 61.5m. 

Chief financial officer Andrew Oakley said: "Actelion now expects, unforeseen events excluded, that both total net revenues and cash EBIT [Earnings Before Interest and Tax] - in local currencies - will increase between 16 and 19 per cent for the full year of 2009."

The company reports a pipeline of 10 compounds in clinical development and 25 active projects in drug discovery.

21st July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...

Infographics